Patent ID: 11903908
Assignee: ADAMAS PHARMA, LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 43:
44. A method of reducing OFF time in a patient with Parkinson's disease (PD), wherein the patient is being treated with levodopa and is experiencing OFF periods, the method comprising:
(1) orally administering to said patient once daily for at least one week a first composition comprising 260 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form; and thereafter
(2) orally administering to said patient once daily a second composition comprising 290 mg to 325 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form;
wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient;
wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the first or second composition; and
wherein the reduction of OFF time is determined in a placebo controlled, double blind clinical study.